Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 4/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.37 |
| ▸ | PRKACA | P17612 | 4/20 | 0.37 |
| ▸ | GSK3B | P49841 | 4/20 | 0.37 |
| ▸ | PIM1 | P11309 | 3/20 | 0.37 |
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | HIPK2 | Q9H2X6 | 3/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.37 |
| ▸ | PAK4 | O96013 | 2/20 | 0.37 |
| ▸ | CDK8 | P49336 | 2/20 | 0.37 |
| ▸ | CLK2 | P49760 | 2/20 | 0.37 |
| ▸ | CDK7 | P50613 | 2/20 | 0.37 |
| ▸ | CDK9 | P50750 | 2/20 | 0.37 |
| ▸ | PRKX | P51817 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.37 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25084683 | 0.84 | CDC7 (0.41) | CDC7MAP4K4PRKACAGSK3BPIM1 | |
| SCHEMBL25084858 | 0.81 | TGFBR1 (0.40) | TGFBR1 | |
| SCHEMBL30156340 | 0.81 | TGFBR1 (0.40) | TGFBR1 | |
| SCHEMBL23408110 | 0.79 | TGFBR1 (0.42) | CDC7MAP4K4PRKACAGSK3BPIM1 | |
| SCHEMBL29796644 | 0.79 | TGFBR1 (0.40) | CDC7MAP4K4PRKACAGSK3BPIM1 | |
| SCHEMBL23389744 | 0.79 | TGFBR1 (0.40) | CDC7MAP4K4PRKACAGSK3BPIM1 | |
| SCHEMBL25084852 | 0.78 | TGFBR1 (0.39) | TGFBR1 | |
| SCHEMBL25084647 | 0.75 | GSK3B (0.47) | CDC7MAP4K4PRKACAGSK3BPIM1 | |
| SCHEMBL23390007 | 0.75 | CHRNB2 (0.40) | TGFBR1 | |
| SCHEMBL29796391 | 0.75 | CHRNB2 (0.40) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11590116-B2 | Substituted pyridines and methods of use | ALK, ACVR1, ACVR2A | CDC7 1194/4885MAP4K4 572/4885PRKACA 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.